RNF39

RNF39 is a RING finger E3 ubiquitin ligase that acts as a substrate-specific regulator of innate antiviral signaling and, in cancer cells, of the ER stress response (PMID:33674311, PMID:39255680, PMID:41457280). It carries N-terminal RING finger and C-terminal B30.2 domains and was first identified as a cytoplasmically localized immediate-early gene product induced in hippocampal granule cells following long-term potentiation (PMID:11716498). In RNA-sensing immunity, RNF39 catalyzes K48-linked polyubiquitination and proteasomal degradation of the RNA helicase DDX3X, thereby dampening RIG-I-like receptor antiviral responses; its loss enhances RNA virus-triggered immunity and restricts viral replication (PMID:33674311). In the DNA-sensing arm, RNF39 conversely promotes K63-linked ubiquitination of STING to facilitate STING-TBK1 complex assembly and accelerate cGAS-dependent type I interferon responses, with HSV-1 inducing RNF39 in an IFN-I-dependent positive feedback loop (PMID:39255680). In colorectal adenocarcinoma, RNF39 is transcriptionally activated by MEF2D and drives tumor progression by targeting RINT1 for K48-linked degradation, suppressing the unfolded protein response, CHOP expression, and ER stress-induced apoptosis in a manner dependent on its E3 ligase activity (PMID:41457280).

1. 2001 Medium

   Established the molecular identity of RNF39 as a RING/B30.2-domain protein and placed it as an activity-induced immediate-early gene, raising the question of what cytoplasmic function its E3-type architecture serves.

   Evidence EGFP fusion live-cell localization in COS-7 cells and in vivo LTP induction with temporal expression profiling

   PMID:11716498

   Open questions at the time

   • No catalytic activity or substrate demonstrated at this stage
   • Functional role of LTP-induced expression in neurons not defined
   • Domain composition inferred from sequence, not biochemically validated as an active ligase
2. 2014 Low

   First functional link of RNF39 to viral biology, indicating RNF39 levels positively influence HIV-1 replication, though without a defined molecular mechanism.

   Evidence RNF39 knockdown in cell lines with HIV-1 replication readout plus correlative haplotype-expression-viral load genetic association

   PMID:25126410

   Open questions at the time

   • Single knockdown experiment without mechanistic pathway detail; haplotype link is correlative
   • No substrate or ubiquitination activity identified
   • Direction of effect not reconciled with later antiviral findings
3. 2021 High

   Defined RNF39 as a bona fide E3 ligase and identified its first substrate, showing it negatively regulates RNA-sensing innate immunity by degrading DDX3X.

   Evidence Reciprocal Co-IP, K48-linkage-specific ubiquitination assay, proteasome inhibitor rescue, and Rnf39 knockout with viral infection and immune reporter readouts

   PMID:33674311

   Open questions at the time

   • Domain requirements (RING vs B30.2) for DDX3X recognition not dissected
   • In vivo organismal relevance not tested
   • Whether DDX3X is the sole RLR-pathway substrate unknown
4. 2024 High

   Revealed RNF39 as a bifunctional immune regulator that, in contrast to its RNA-pathway role, positively drives DNA-sensing immunity via non-degradative K63 ubiquitination of STING.

   Evidence Reciprocal Co-IP, K63-specific ubiquitination assay, STING-TBK1 complex formation assay, and Rnf39 knockdown/knockout with HSV-1 infection and IFN-I reporter readouts

   PMID:39255680

   Open questions at the time

   • Structural basis for K48 vs K63 linkage choice between substrates unknown
   • STING ubiquitination site not mapped
   • How opposing RNA and DNA pathway roles are coordinated in a single cell unresolved
5. 2026 High

   Extended RNF39 beyond immunity to oncogenesis, identifying RINT1 as a degradation substrate and MEF2D as an upstream transcriptional activator that together drive colorectal cancer by limiting ER stress apoptosis.

   Evidence Co-IP, K48-linked ubiquitination assay, shRNA/CRISPR knockout, overexpression and double-knockdown epistasis rescue, in vivo xenograft, ChIP and luciferase reporter assays

   PMID:41457280

   Open questions at the time

   • Whether RINT1 degradation occurs in non-cancer or immune contexts not addressed
   • Connection between RNF39's immune substrates and its tumor role unexplored
   • RINT1 recognition determinants on RNF39 not mapped
6. 2026 Medium

   Identified an upstream antagonist of RNF39 activity, showing SEC14L4 stabilizes DDX3X by blocking RNF39-mediated ubiquitination in esophageal squamous cell carcinoma.

   Evidence Co-IP with mass spectrometry, ubiquitination assay, shRNA knockdown and DDX3X-overexpression rescue, in vivo tumor models

   PMID:41741625

   Open questions at the time

   • RNF39 role inferred from inhibition by SEC14L4 rather than direct RNF39 manipulation
   • Mechanism by which SEC14L4 shields DDX3X from RNF39 not defined
   • Whether SEC14L4 affects RNF39's other substrates unknown

• How RNF39 selects between K48 (degradative) and K63 (non-degradative) ubiquitination across its substrates, and what governs its opposing roles in RNA versus DNA antiviral sensing, remains unresolved.
• No structural model linking RING/B30.2 domains to substrate or linkage selection
• No study integrating its neuronal, antiviral, and oncogenic functions
• Regulation of RNF39 abundance/activity outside IFN-I and MEF2D inputs uncharacterized